ME/CFS
-
Research updates, February 24
SARS-C0V-2 reinfections significantly increase the risk of Long COVID in children, a new National Institutes of Health (NIH) RECOVER study found.
-
Research updates, February 10
A large study recently connected “chronic absenteeism” to pediatric Long COVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic.
-
Metrodora promised comprehensive treatment. But within two years, it abruptly closed.
The clinic sought to cure “neuroimmune disorders” like Long COVID and myalgic encephalomyelitis. Former patients feel betrayed.
-
Research updates, December 23
Two recent studies state that Long COVID is an occupational disease.
-
Telehealth is vital for people with Long COVID. Don’t let it disappear.
Changes to telehealth policies are more than an inconvenience. For many of us, critical infrastructure is in jeopardy, and we urgently need government policy to protect it.
-
“Medically neglected” and “structurally erased”: International network appeals for ME advocate Nevra Elis
This fall, an international group of people known as Team Nevra has led an ongoing campaign to fundraise and help find care for Nevra Elis, an advocate living with severe myalgic encephalomyelitis (ME).
-
Less than 20% of Long COVID trials involving exercise even mention post-exertional malaise
An analysis by The Sick Times find that less than 15% of Long COVID clinical trials testing the benefits of exercise or cardiopulmonary rehabilitation measured post-exertional malaise, according to their trial registration, while a handful excluded participants who experience it.
-
Long COVID advocacy is more than lobbying Congress: Here are some ways to get involved
People with infection associated chronic conditions (IACCs) use a broad range of strategies to fight for awareness and better care.
-
Research updates, October 28
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
-
Research updates, October 21
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
A new aid in the doctor’s office: Introducing the Long COVID Treatment Guide
-
Where have all the Long COVID clinics gone?
-
National COVID-19 trends, March 10
-
Research updates, March 10
-
My child and I both have Long COVID. Even in COVID-aware spaces, we are excluded because of their pre-existing disability.
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance